FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry and represents a liquid pharmaceutical composition for improving at least one medical condition requiring administration of an adrenergic compound into an individual; the pharmaceutical composition contains the adrenergic compound, wherein the adrenergic compound is epinephrine or its physiologically acceptable salt, and at least one antioxidant specified in a group consisting of bisulphite, metabisulphite and sulphite compounds, wherein a molar ratio of the adrenergic compound to at least one antioxidant measured as a sulphite equivalent falls within the range of 0.70-1.30 and wherein the pH value of the above liquid composition falls within the range of 2.0-5.0.
EFFECT: invention provides higher storage stability with substantially reduced sensitivity to induced light, thermal and oxidative degradation.
17 cl, 9 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABILISED COMPOSITION CONTAINING AT LEAST ONE ADRENERGIC COMPOUND | 2010 |
|
RU2527337C9 |
| PHARMACEUTICAL COMPOSITION ELICITING ANESTHETIC ACTIVITY | 2004 |
|
RU2261092C1 |
| DETERGENT WITH STABILISED ENZYME SYSTEMS | 2007 |
|
RU2441062C2 |
| ABT-263 CAPSULE | 2010 |
|
RU2550956C2 |
| STABILISED LIPID PREPARATIVE FORM OF APOPTOSIS PROMOTER | 2010 |
|
RU2530642C2 |
| COMPOSITIONS, INCLUDING PROTEIN AND CATIONIC POLYMER, AND POSSESSING LOWER VISCOSITY | 2009 |
|
RU2523314C2 |
| MUCOADHESIVE PHARMACEUTICAL COMPOSITIONS BASED ON CORTICOSTEROIDS | 2019 |
|
RU2805936C1 |
| MEDICATION, POSSESSING VENOMOTOR AND ANTICOAGULANT ACTION (VERSIONS) | 2012 |
|
RU2548785C2 |
| LIQUID FOR PROCESSING NEAR-WELLBORE ZONE USING SYSTEM AND OXIDANT-BASED LIQUEFACTION METHOD | 2009 |
|
RU2490297C2 |
| COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND USING THEM | 2013 |
|
RU2688672C2 |
